Home › Funds › EMERALD ADVISERS, LLC › SYRE

EMERALD ADVISERS, LLC position in SYRE

SPYRE THERAPEUTICS INC · Health Care

EMERALD ADVISERS, LLC reported holding 571,047 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$50.8M, representing 1.40% of its reported portfolio and ranking #14 among its reported holdings. EMERALD ADVISERS, LLC has disclosed SYRE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)571.05K sh
Reported value held$50.84M
Portfolio Weight1.40%
First reportedQ3 2024
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How EMERALD ADVISERS, LLC's SYRE position evolved

EMERALD ADVISERS, LLC first disclosed a stake in SYRE in Q3 2024 at 292,569 shares (US$8.6M). The position peaked in Q3 2026 at 571,047 shares, worth US$50.8M. Across 9 filings, EMERALD ADVISERS, LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 571,047 shares valued at US$50.8M — an increase of 3,617 shares quarter over quarter.. Notable position changes include a 87% increase in Q4 2024 (shares fell 31% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 292.57K $8.60M New
Q4 2024 546.79K $12.73M Add
Q1 2025 547.83K $8.84M Hold
Q2 2025 565.86K $8.47M Add
Q3 2025 548.71K $9.20M Reduce
Q4 2025 636.11K $20.84M Add
Q1 2026 613.37K $30.94M Reduce
Q2 2026 567.43K $50.38M Reduce
Q3 2026 571.05K $50.84M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has EMERALD ADVISERS, LLC held SYRE?

EMERALD ADVISERS, LLC has disclosed SYRE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is EMERALD ADVISERS, LLC's current position in SYRE?

As of Q3 2026, EMERALD ADVISERS, LLC holds 571.05K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $50.84M, representing 1.40% of its reported portfolio and ranking #14.

Has EMERALD ADVISERS, LLC been buying or selling SYRE?

In the latest 13F filing (Q3 2026), EMERALD ADVISERS, LLC increased its position in SYRE. The position peaked in Q3 2026 at 571.05K shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 66 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.